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ABSTRACT
Introduction: Nowadays, diagnosis of brain tumours is mainly carried out via neuroimaging techniques. 
The most widespread methods for routine analysis include computer tomography and magnetic resonance 
imaging. While such methods are useful to localise tumours, they are unable to offer a conclusive diagnosis 
of the tumour type. A final diagnosis can only be made via a histological examination of tissue after tumour 
resection, or, in cases where the location of the tumour is not amenable to resection, after a biopsy of the 
tumour is carried out. Untargeted metabolite analysis is a relatively new approach to diagnostics, capable 
of establishing wide characterisation of endogenous metabolites of a given system, a method that can be 
applied to improve identification of tumour types via biomarker discovery. In this regard, sample collection 
and preparation can be said to be the most important step in metabolomic studies.
Material and methods: In the current study, a solid phase microextraction (SPME) protocol for metabolo-
mics, which has been successfully applied towards metabolite analysis in various biological materials in 
the last few years, was optimised for brain tumour tissue metabolomic analysis. In the current study, the 
described approach was applied to human brain tumours. Aiming to incur minimal tissue damage, the 
probes used for sampling were of diameter ca. 0.2 mm. Aiming to optimise the method towards enhanced 
recovery of the extracted metabolites, various desorption solvents were tested in an optimisation study. 
The final protocol was used for analysis of a pilot cohort of patients with glioma and meningioma tumours.
Results: The results showed that a protocol where chemical biopsy was performed directly from resected 
tumour with 7-mm-long coating SPME probe and desorption was done using 0.3 mL of a mixture of 
acetonitrile and water 80:20 v/v was superior to other tested protocols. The optimised method allowed for 
successful differentiation between the two types of brain tumours studied: meningioma and glioma. Despite 
the relatively small cohort group involved in the study, several compounds were tentatively identified as 
statistically significant metabolites responsible for this differentiation. 
Conclusions: The presented preliminary data demonstrate a potential of the proposed method as a low 
invasive diagnostic tool for on-site analysis.
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Introduction
Despite the considerable scientific progress made 
in the neuro-oncology field within recent decades, 
brain tumours continue to carry a high rate of mortality 
and morbidity, with many types of brain tumour still 
considered to be incurable and terminal. For instance, 
despite undergoing radiation therapy, the average life 
expectancy of patients diagnosed with glioblastoma 
multiforme, the most aggressive type of brain cancer, 
is only 12.1 months. [1] While the first classification 
of brain tumours was established in 1979, remaining 
unchanged for nearly 10 years, revised classifications 
have since been introduced owing to the significant 
amount of research carried out on the central nervous 
system and its diseases, including tumours [2]. While 
initial classifications were based on the histological 
origin of a given type of cancer, histology-based di-
agnoses have since been shown to not always match 
the clinical profile of a given cancer [3]. Because the 
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correct classification and diagnosis of tumour type and 
subtype play a very important role in the prediction 
of response to a given treatment, significant scientific 
interest has been paid to the identification of molecular 
biomarkers of brain tumours, which can be used to 
complement histological testing, and thus aid in more 
accurate diagnoses. To that extent, the genotyping 
and identification of certain mutations have already 
been proven to be a promising prognostic tool in the 
treatment of gliomas [3], one of the most widespread 
types of central nervous system tumours, constituting 
approximately 60% of all primary brain tumours [4,5]. 
However, the genotype of an individual is not the 
only biological determinant of a tumour; for instance, 
factors such as hyperglycaemia or elevated BMI may 
also predispose patients to the development of glioma 
[4, 5]. To this end, metabolite profile determinations 
aid in the identification of the phenotype of a given 
tumour, which reflects all factors that influence tissue 
biochemistry, including environmental, demographic, 
physiological, and pathological factors, among oth-
ers [6]. Owing to the development of new analytical 
methods such as nuclear magnetic resonance (NMR), 
spectroscopy, and mass spectrometry (MS), today sci-
entists are able to gain better insight into the biochem-
ical secrets of the human body that trigger diseases, 
including the ones associated with the growth and 
progression of brain tumours [5]. Because gliomas 
constitute some of the most common and malignant 
brain cancers, elucidations of the metabolomic pro-
files of gliomas may broaden the therapeutic options 
for these types of tumours. The relatively low response 
of brain tumours to treatment, including that of glio-
mas, poses an immense challenge for clinicians and 
researchers. Today, implementation of radiotherapy 
coupled with temozolomide is the most prescribed 
course of treatment for many brain tumours; however, 
considering the still high morbidity and mortality of 
brain tumours, further broadening of scientific knowl-
edge regarding different types of brain tumours, as 
well as their biochemical foundation, can contribute to 
the development of more effective treatments targeted 
at specific tumour types, which will in turn contribute 
to increased chances of survival for patients afflicted 
by such conditions. [7]. In addition, the timeframe 
of analysis also plays an important role in improved 
diagnosis of brain tumours; in many cases, surgeons 
depend on intraoperative results for diagnosis, which 
in some cases, like histological testing, might become 
obsolete. In view of the lack of sufficiently fast and 
precise diagnostic tools available to date, further 
development of real time or on-site rapid diagnostic 
tools is needed to guide medical personnel towards 
optimal diagnosis and course of treatment [8]. Cer-
tainly, fast analysis protocols would enable doctors 
to make immediate decisions regarding the course 
of treatment, which would in turn contribute to an 
increased chances of therapeutic success. 
Solid phase microextraction (SPME) is an analytical 
platform with demonstrated capability, having shown 
great potential towards tissue analysis applications, in-
cluding both ex vivo and in vivo analyses. The integrated 
sampling and extraction process is characterised by 
minimum invasiveness and lack of sample consumption 
because SPME can be applied to extract molecules 
directly from intact tissue in a negligible manner [Fig. 
1]. Owing to these features, following SPME sampling, 
the biopsy or resected tissue can be used for further 
analysis, i.e. histological testing or genotyping [9]. 
The most common geometry of the SPME device is 
the fibre, which can be described as a metal alloy wire 
with a dimension of ca. 0.2 mm, which consists of a tip 
coated with an extraction phase. The device is made 
of biocompatible materials that prevent adhesion of 
biological materials to the fibre, while also averting con-
tamination of the sample, which is particularly crucial in 
living tissue applications. Detailed information regarding 
the technology and its utilisation in bioanalysis can 
be found elsewhere [10–13]. In the present study, the 
development of a method allowing for in situ and in 
vivo metabolic profiling of brain tumours is presented. 
Here, an evaluation of the feasibility of the method to 
distinguish the tumour type based on the metabolic 
phenotype was carried out via analysis of sets of menin-
Figure 1. SPME extraction from a tumour, performed 
immediately after resection
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gioma and glioma tumours, with results demonstrating 
the capability of the method to differentiate tumours 
based on their phenotype. 
Materials and methods
The study was approved by the Bioethics Com-
mittee of Collegium Medicum in Bydgoszcz at Nico-
laus Copernicus University in Torun (KB 628/2015). 
Sample preparation was performed via SPME in fibre 
format. The coating of fibres used in this experiment 
consisted of a mix of C18 and strong cation exchange 
(SCX) particles. Coatings were preconditioned in 
1.5 ml methanol/water solution 50/50, v/v for one 
hour before extraction. Next, the fibres were stati-
cally washed in 1.5 ml water for five seconds, and 
subsequently introduced to resected brain tumour 
tissue (Fig. 1). 
The static extraction process was executed for 
30 minutes, followed by a five-second static wash 
step with water. To select the optimum conditions, 
the desorption step was carried out with the use of 
seven desorption solvent mixtures, as follows: aceto-
nitrile/methanol/water, 25/25/50, v/v/v (solution #1); 
acetonitrile/methanol/water, 50/25/25, v/v/v (solution 
#2); acetonitrile/methanol/water, 25/50/25, v/v/v (solu-
tion #3); acetonitrile/water, 80/20, v/v (solution #4); 
acetonitrile/water, 80/20, v/v further diluted with ace-
tonitrile 50:50 v/v (solution #4.1; a reference solution, 
used in the previous metabolomics analysis with SPME 
[12]); acetonitrile/water, 20/80, v/v (solution #5); ace-
tonitrile/water, 50/50, v/v (solution #6). The volume 
of desorption solvent was 0.3 mL in each case. The 
desorption process was continued for 120 min with 
agitation set at 1200 rpm, using a BenchMixer™ Mul-
tiTube Vortexer (Benchmark Scientific, Edison, USA). 
The LC–MS grade chromatographic solvents methanol, 
acetonitrile, water, and formic acid, as well as ammoni-
um acetate used for buffer preparation were purchased 
from Sigma-Aldrich (Poznań, Poland). 
LC-MS/MS analysis
Experiments were carried out on a Q Exactive Focus 
Orbitrap (Thermo Fisher Scientific) coupled to a Dionex 
UHPLC system. Chromatographic separation was car-
ried out with the use of a hydrophilic stationary phase 
HILIC column (Luna HILIC 100 mm x 2.0 mm, 3 µm, 
Phenomenex) as well as in reversed-phase using a pen-
tafluorophenyl (PFP) column (Discovery HS F5 100 x 
2.1 mm, 3 µm, an in-kind gift from Supelco, Bellefonte, 
PA, USA). The flow rates were 400 µl min-1and 300 µl 
min-1 for HILIC and PFP columns, respectively. The 
chosen mobile phases for the reversed phase column 
were water with formic acid (99.9:0.1; v:v) (A) and 
acetonitrile with formic acid (99.9:0.1) (B), while mobile 
phases for the HILIC column consisted of acetonitrile 
with 20 mM ammonium acetate buffer (90:10, v:v) (A) 
and acetonitrile with 20 mM ammonium acetate buffer 
(50:50; v:v) (B). The injection volume was 10 µl. The gra-
dients of both methods used in this study were adopted 
from Vuckovic et al. [14]. Analyses were performed in 
positive and negative electrospray ionisation modes, 
with total run times per sample of 20 and 40 minutes for 
the HILIC and PFP methods, respectively. Processing 
and data acquisition were performed on a Compound 
Discoverer 2.1, an in-kind contribution from Thermo 
Fisher Scientific.
Statistical analysis was performed using Principal 
Component Analysis (PC) and ANOVA; the P-value ad-
justment was calculated using the Benjamini-Hochberg 
procedure to establish the false-discovery rate. 
Results
In SPME applications, the selection of an appro-
priate extraction phase and desorption solvent plays 
a large role in the attainment of adequate extraction 
efficiency. In this study, a mix-mode extraction phase 
was selected based on its previously reported superior 
performance for metabolomic analysis [15]. The current 
work also included a desorption solution optimisation 
study aimed at a performance comparison of seven 
solvents, utilising factors such as signal intensity and 
number of detected features on each LC column, in 
positive and negative ionisation modes, as performance 
parameters. As can be seen in Fig. 2, analyte coverage 
varied at different desorption conditions. The lowest 
number of features appeared on the HILIC column in 
both positive and negative modes when desorption 
solutions 1 and 5 were used (56 and 38; 49 and 46, re-
spectively, for positive and negative modes). The same 
trend was observed for desorption solutions 1 and 5 for 
the PFP column, in both ionisation modes (132 and 95; 
145 and 88, respectively). 
Among the compared solutions, the largest number 
of features detected by both columns and in both ioni-
sation modes was observed for ACN/H2O, 80/20 as the 
desorption solvent. The number of features detected 
by the HILIC column in positive and negative ionisation 
modes were 137 and 119, respectively, and analo-
gously 394 and 149 for the PFP column in positive and 
negative ionisation modes, respectively. Furthermore, 
this desorption solution significantly increased peak 
areas and, consequently, the sensitivity of the method 
as compared to the other tested solvents. Particularly, 
for the reversed phase method with the PFP column, 
employment of this desorption solution yielded almost 
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Figure 2. Comparison of number of features detected by HILIC and PFP column in positive and negative ionisation 
modes for six desorption solution mixtures (#1 ACN/MeOH/H2O, 25/25/50, v/v/v; #2 ACN/MeOH/H2O, 50/25/25, v/v/v; 
#3 ACN/MeOH/H2O, 25/50/25, v/v/v; #4 ACN/H2O, 80/20, v/v; #4.1 ACN/H2O, 50/50, v/v further diluted with ACN 50:50 v/v; 
#5 ACN/H2O, 20/80, v/v; #6 ACN/H2O, 50/50, v/v)
twice as many compounds as compared to that at-
tained via the other tested solutions [Fig. 2]. The S-plot 
shows the multiplicity of features, differentiating the 
tested desorption solvents as well as denoting which 
compounds detected by the selected desorption sol-
vent go otherwise undetected when employing any of 
the other five desorption solutions. Figure 3 includes 
a Box-Whisker chart of one such discriminating com-
pound marked in the S-plot [Fig. 2], as well as the 
chromatograms for this compound obtained for differ-
ent desorption solvents. 
Analyte coverage and intensity of extracted endog-
enous compounds for HILIC and PFP methods are 
presented in Figures 4 and 5, respectively. 
Following protocol optimisation, pilot studies were 
performed on resections of tumours of patients with 
glioma (HGG) and meningioma tumours (n = 11 and 
17, respectively). The principal component analysis 
plot shown in Figure 6 demonstrates clear separation 
of data for the two patient groups.
Discussion
Solid phase microextraction, which can be de-
scribed as an equilibrium-based, non-exhaustive 
sample preparation method, has been successfully 
demonstrated for untargeted metabolomics and in 
vivo studies [16–17]. However, as the diversity of the 
tissues, their heterogeneity, as well as the biochemistry 
of the given tissue can influence method performance, 
additional tuning of some parameters in the general 
protocol might allow for an increase in detection limits, 
as well as aid in the attainment of superior results for 
chromatographic measurements. For this purpose, 
additional efforts were expended to optimise the SPME 
protocol proposed by Risticevic et al. towards the 
currently discussed application [18]. In the present 
study, a straight-forward strategy was applied to 
prepare a final protocol that enables the detection of 
more endogenous metabolites in comparison to that 
afforded by the originally proposed method, which in 
turn should enhance differentiation of various types 
of brain tumours. The goal of the optimisation study 
carried out in this work included the selection of 
a desorption solution that could be directly subject-
ed to both types of chromatographic modes: HILIC 
and reversed phase. Furthermore, the optimisation 
parameters included selection of a suitable solution 
that dispensed with the need for extract dilution with 
acetonitrile, a procedure often carried out to make the 
extractant more compatible with the HILIC column, 
which requires a higher content of organic solvent to 
obtain acceptable peak shapes. Such a dilution sig-
nificantly affects overall sensitivity and, consequently, 
the quality of the results. Conversely, increasing the 
organic content and compromising water content 
could potentially affect the recovery of polar com-
pounds. As such, method optimisation necessitated 
a careful and comprehensive comparison of various 
desorption solutions. 
As expected, diluted extracts yielded a much lower 
number of detected molecular features, as can be seen 
in Fig. 2. In HILIC separation, more polar compounds 
elute later and reverse, and fewer polar compounds 
elute at the beginning of the chromatographic run. As 








































Figure 3. Endogenous compound m/z 268.0808. Top panel: Chromatograms of signal intensities for the selected 
compound for the six different mixtures of desorption solutions on the HILIC column in negative ionisation mode 
(#1 ACN/MeOH/H2O, 25/25/50, v/v/v; #2 ACN/MeOH/H2O, 50/25/25, v/v/v; #3 ACN/MeOH/H2O, 25/50/25, v/v/v; 
#4 ACN/H2O, 80/20, v/v; #5 ACN/H2O, 20/80, v/v; #6 ACN/H2O, 50/50, v/v). Bottom panel: S-plot and Box-Whisker 
chart for selected compound on HILIC column in negative ionisation mode
demonstrated in Fig. 4, higher content of water in the 
mobile phase resulted in lower sensitivities, even in 
cases where the extract injected on the column was 
not diluted. Addition of acetonitrile, on the other hand, 
increased not only the detectability of fewer polar 
compounds, but also of compounds that eluted at the 
end of the chromatographic gradient, i.e. most polar 
species. While results from the PFP column did not 
yield such pronounced differences between subsequent 
desorption solvents as those attained for the HILIC 
column, they nonetheless corroborated the confirmed 
superior performance of the ACN/H2O 80:20 (v/v) 
solution as desorption solvent. As such, the ACN/H2O 
80:20 (v/v) solution was selected as desorption solvent 
for the final protocol.
Validation of the clinical applicability of the method 
was carried out using a relatively small patient cohort; 
nonetheless, effective separation between groups was 
achieved, based on the two first principal components 
(PC1 22% and PC2 12.4%). Although the small size 
of the studied cohort impedes the establishment of 
conclusive findings of a biological or clinical nature, 
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Figure 4. Comparison of analyte coverage for the six desorption solvents used, with separation carried out on HILIC column.


































Figure 6 A. Principal component analysis showing differentiation of meningiomas (light blue) and gliomas (dark blue); 
B. example of a discriminant compound for glioma and meningioma differentiation, putatively identified as ophthalmic acid
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the obtained results nonetheless revealed several com-
pounds as possible biomarkers of these tumours. To 
demonstrate the applicability of the proposed ap-
proach for further biomarker studies, an example 
of one such discriminative metabolite is presented 
in Fig. 6. Identification of this compound was per-
formed based on its accurate mass via a comparison 
of experimental data with databases included in the 
Compound Discoverer 2.1 software (which includes 
the Human Metabolome Database and ChemSpider, 
among others). This compound, tentatively identified 
as ophthalmic acid, has been previously reported in 
the literature as a biomarker of oxidative stress [19]. 
In the current study, this compound was shown to be 
present in distinctively higher levels in meningioma 
tissue. The proposed analytical protocol is currently 
being used in further studies based on a larger cohort 
of patients with the aims of finding potential biomarkers 
of high- and low-grade gliomas, as well as establishing 
different phenotypes of gliomas.
Conclusions
The aims of the current study were to improve the 
metabolomics sample preparation protocol in terms 
of increasing desorption efficiency, and to validate 
the protocol applicability for metabolomic analysis, 
particularly aimed at the discovery of biomarkers of 
different brain tumours. According to the experiments 
performed in the current study, the use of SPME fi-
bres for extraction, use of the optimised desorption 
solution, and separation via high-resolution mass 
spectrometer provided an appropriate workflow for 
comprehensive brain tumour metabolomic analysis, 
using both reversed phase and HILIC chromatography 
in positive and negative ionisation modes. The evalu-
ation clearly demonstrated that analyte coverage, in 
particular when using the HILIC method, was improved 
in comparison to that achieved via the previously 
described protocol proposed by Risticevic et al., 
from which the optimised protocol was adapted. The 
currently proposed optimised protocol increases the 
probability of finding unique biomarkers of tumours in 
future studies. To that end, the proposed strategy was 
applied in a validation study to find specific endogenous 
metabolites capable of differentiating between various 
types of brain tumour tissues, with clear separation 
attained between groups.
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